Acrivon Therapeutics Inc
(ACRV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,756 | -31,167 | -22,238 | -13,040 | -7,220 |
| Depreciation Amortization | -1,008 | -334 | 57 | 123 | 45 |
| Accounts payable and accrued liabilities | 470 | -245 | 482 | 449 | -95 |
| Other Working Capital | -430 | -1,532 | 335 | -1,957 | -1,461 |
| Other Operating Activity | 2,367 | 3,161 | 601 | 183 | 313 |
| Operating Cash Flow | $-11,357 | $-30,117 | $-20,763 | $-14,242 | $-8,418 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 9,352 | -139,510 | -44,694 | N/A | N/A |
| PPE Investments | -25 | -2,166 | -1,915 | -1,489 | -415 |
| Investing Cash Flow | $9,327 | $-141,676 | $-46,609 | $-1,489 | $-415 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 104,482 | 24 | 0 | N/A |
| Other Financing Activity | 0 | -2,773 | -175 | -11 | 0 |
| Financing Cash Flow | $N/A | $101,709 | $-151 | $-11 | $N/A |
| Beginning Cash Position | 29,907 | 99,991 | 99,991 | 99,991 | 99,991 |
| End Cash Position | 27,877 | 29,907 | 32,468 | 84,249 | 91,158 |
| Net Cash Flow | $-2,030 | $-70,084 | $-67,523 | $-15,742 | $-8,833 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,357 | -30,117 | -20,763 | -14,242 | -8,418 |
| Capital Expenditure | -25 | -2,166 | -1,915 | -1,489 | -415 |
| Free Cash Flow | -11,382 | -32,283 | -22,678 | -15,731 | -8,833 |